Living Cell Technologies Limited

ACN: 104 028 042
ASX: LCT
OTCQX: LVCLY

ASX ANNOUNCEMENT

Results of Annual General Meeting held on 10 November 2022

Sydney, Australia & Auckland, New Zealand, 10 November 2022 - Living Cell Technologies Limited (ASX: LCT; OTCQB: LVCLY) advises the results of the 2022 Annual General Meeting in accordance with Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act. Details are set out in the attached document.

Authorised for release by the Board of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

At the Company:	For media queries:
Bradley Dilkes Director Mobile: +61 422 180 317 brad@lctglobal.com	Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX:LCT) and US (OTCQB:LVCLY) stock exchanges. The Company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information, visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.

Forward-looking statements

This document may contain certain forward-looking statements, relating to LCT's business, which canbe identified by the use of forward-looking terminology such as "promising," "probable", "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be,""on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCTis providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developmentsor otherwise.

Living Cell Technologies Limited
Annual General Meeting
Thursday, 10 November 2022
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of the Remuneration Report	Ordinary	698,381,031 98.22%	11,480,723 1.61%	1,230,693 0.17%	5,411,736	700,759,825 98.39%	11,480,723 1.61%	5,511,736	Carried
2 Re-election of Mr Robert Willcocks as a Director	Ordinary	118,840,191 16.60%	595,546,063 83.20%	1,435,693 0.20%	918,571	Resolution withdrawn			Not Applicable
3 Re-election of Dr Andrew Kelly as a Director	Ordinary	124,198,299 17.35%	590,396,526 82.45%	1,435,693 0.20%	710,000	Resolution withdrawn			Not Applicable
4 Ratification of 257,000,000 Placement shares issued on 3 June 2022	Ordinary	382,615,538 92.68%	28,836,374 6.98%	1,415,050 0.34%	299,903,556	384,156,688 92.79%	29,858,375 7.21%	299,903,556	Carried
5 Amendments to the Constitution	Special	703,593,568 98.91%	6,341,521 0.89%	1,453,693 0.20%	5,381,736	705,173,361 98.97%	7,363,522 1.03%	5,481,736	Carried
6 Approval of 10% Placement Facility	Special	685,321,775 98.85%	6,424,041 0.93%	1,539,050 0.22%	23,485,652	686,986,925 98.93%	7,446,042 1.07%	23,585,652	Carried
7 Appointment of Director - Mr David Richard Hainsworth	Ordinary	585,884,034 81.83%	128,699,434 17.97%	1,447,050 0.20%	710,000	Resolution withdrawn			Not Applicable
8 Appointment of Director - Mr Bradley John Dilkes	Ordinary	585,664,034 81.80%	128,919,434 18.00%	1,447,050 0.20%	710,000	Resolution withdrawn			Not Applicable
9 Removal of Director - Professor Bernard Tuch	Ordinary	580,640,662 81.09%	133,968,971 18.71%	1,420,885 0.20%	710,000	Resolution withdrawn			Not Applicable
10 Removal of Director - Dr Andrew Kelly	Ordinary	592,875,783 82.80%	121,739,685 17.00%	1,415,050 0.20%	710,000	Resolution withdrawn			Not Applicable
11 Removal of Director - Mr Robert Moyse Willcocks	Ordinary	598,025,320 83.52%	115,780,148 16.17%	2,225,050 0.31%	710,000	Resolution withdrawn			Not Applicable
12 Removal of Interim Appointed Directors	Ordinary	585,151,101 81.97%	127,316,853 17.83%	1,415,050 0.20%	2,857,514	Resolution withdrawn			Not Applicable
13 Elect David Richard Hainsworth as a Director	Ordinary	276,760,595 99.21%	2,150,685 0.77%	60,800 0.02%	5,700,000	277,908,696 99.16%	2,355,685 0.84%	5,760,800	Carried
14 Election of Mr Bradley John Dilkes as a Director	Ordinary	281,760,595 99.22%	2,150,685 0.76%	60,800 0.02%	700,000	282,969,496 99.17%	2,355,685 0.83%	700,000	Carried